Navigation Links
Obio Pharmaceutical Announces Product Growth Strategy
Date:2/18/2009

n antiviral drug candidate -- TG21 that could tackle avian and human influenza virus. Thanks to the US Food and Drug Administration (FDA) and EU European Medicines Agency (EMA) previous approval of the active ingredient of TG21 as an orphan drug, its safety profile is assured. As cases of resistance to the mainstream medical intervention -- Tamiflu are on the rise, TG21 can be considered an alternative drug preparing for possible pandemic threat. TG21 works on a different mechanism to that of both Tamiflu and Relenza, which are Neuraminidase Inhibitors. TG21 does not work on the same target so the influenza virus is less likely to develop resistance to TG21.

A US Patent Attorney has prepared a patentability report for TG21, application of patents has also been filed on TG21 and pending approval. As a drug research and discovery company, Obio is in process to apply for a fast track mode to accelerate drug registration given the needs of effective treatment for lethal influenza viruses are unmet, and actively negotiating partnership with large pharmaceuticals companies to produce the drug.

Apart from the aforementioned drug candidates, the Company continues to push research of its candidates in life-style and Parkinson disease arenas. The Company believes that its research focus will achieve the Company vision to research and develop novel drugs, and bring them into the market through co-development with other prestigious pharmaceutical companies.

Dr. Bill Chan, Director and Chief Technical Officer of the Company, said, "All the drug candidates on hand should be able to capture the attention from the pharmaceutical industries. Some of them have high chance to become blockbuster drugs after analyzing the market demand. Now, Obio holds all the aces and ready to launch its products; the growth strategy in launching the blockbuster drugs together with other pharmaceutical companies will certainly accelerate
'/>"/>

SOURCE Obio Pharmaceutical Holdings Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2008 Results Conference Call on Thursday, February 26, 2009
2. Romark and Chugai Pharmaceutical Enter Into Exclusive Licensing Agreement for Nitazoxanide in Japan
3. Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results
4. TechniKroms Biopharmaceutical Equipment Operations to be Integrated With Asahi Kasei Medical
5. Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009
6. Vion Pharmaceuticals Submits New Drug Application for Onrigin(TM)
7. Shengtai Pharmaceutical, Inc. Reports Second Quarter Fiscal 2009 Financial Results
8. Genesis Pharmaceuticals Announces Conference Call to Discuss Results for its Second Quarter of FY 2009
9. XTL Biopharmaceuticals Announces Appointment of David Grossman and Boaz Shweiger to Board of Directors
10. Global Biopharmaceutical Leader in Peptide Research Expands Commitment in San Diego/U.S. With New R&D Facility and Ready-To-Market Prostate Cancer Treatment Degarelix
11. Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2009 Second Quarter Earnings Conference Call on Wednesday, February 18, 2009 at 8:45 a.m. EST
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/13/2014)... Boehringer Laboratories Inc., with a forty ... announce the successful broadcast of a live surgery by ... MD, FACS, FAMBS, and Maher El Chaar, MD, FACS, ... , This sleeve gastrectomy surgery was performed and ... four hundred surgeons from around the world during the ...
(Date:9/12/2014)... , Sept. 12, 2014   Arthur Kay ... bio-bean, has won the Postcode Lottery Green Challenge 2014. ... Kay euro 500,000 ($680,000 USD) at the final in ... business plan. Kay,s company uses a ... biofuel products, namely biodiesel and biomass pellets, used for ...
(Date:9/12/2014)... 2014 Research and Markets has ... Photoresist Industry Report 2014" report to their offering. ... Report 2014 is a professional and in-depth study on ... industry . The report provides a basic ... industry chain structure. The dry film photoresist market analysis ...
(Date:9/12/2014)... LONDON , September 12, 2014 ... 4,591.81, up 0.12%, the Dow Jones Industrial Average finished the ... at 1,997.45, up 0.09%. The gains were broad based as ... The S&P 500 Health Care Sector Index ended the day ... in the last one month. Investor-Edge has initiated coverage on ...
Breaking Biology Technology:Boehringer Laboratories, Inc. Announces Live Surgery Using Innovative System to Calibrate Sleeve Gastrectomy 2Green Startup Bio-Bean Wins $680,000 in Postcode Lottery Green Challenge 2Green Startup Bio-Bean Wins $680,000 in Postcode Lottery Green Challenge 3Global Dry Film Photoresist Industry Report 2014 2Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 2Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 3Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 4Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 5
... Australia, January 23, 2012 Ansell Limited ... it has entered into a multi-year agreement with Koreca ... a leading hand protection specialist in Korea. ... Koreca Industries its exclusive distributor of Industrial and New ...
... 23, 2012   BioLife Solutions , Inc. (OTCBB: BLFS), ... hypothermic storage and cryopreservation freeze media ... additional key opinion leaders in the biobanking , ... markets have joined the Company,s Scientific Advisory Board ...
... Scientists at deCODE Genetics and academic ... report the discovery of variants in the human genome ... risk of thyroid cancer.The paper ,Discovery of common variants ... is published today in the online edition of ...
Cached Biology Technology:BioLife Solutions Adds Clinical and Commercialization Experts to Scientific Advisory Board 2BioLife Solutions Adds Clinical and Commercialization Experts to Scientific Advisory Board 3BioLife Solutions Adds Clinical and Commercialization Experts to Scientific Advisory Board 4BioLife Solutions Adds Clinical and Commercialization Experts to Scientific Advisory Board 5deCODE Genetics, in Collaboration with Academic Colleagues, Discovers Three Variants in the Sequence of the Human Genome that Affect the Risk of Thyroid Cancer 2
(Date:9/16/2014)... PALM BEACH GARDENS, Fla. , Sept. 16, ... provider of biometric identity management solutions, announced today ... handheld solution designed to authenticate the identity of ... The Android-based Verifier Sentry rapidly reads ... the credential holder,s ID by matching the biometric ...
(Date:9/15/2014)... 15, 2014) The so-called central dogma of ... long provided a simplified explanation for how genetic ... , In reality, of course, the process ... articulated nearly 60 years ago by Nobel Laureate ... For one, there are multiple types of RNA, ...
(Date:9/15/2014)... single group of microorganisms may be responsible for much ... with implications for the global carbon cycle and climate ... required by most life on this planet, it is ... because it is so large and complex. For humans, ... brain and nervous systems, as well as DNA synthesis ...
Breaking Biology News(10 mins):Cross Match Launches New Identity Management Handheld Solution 2Scientists discover RNA modifications in some unexpected places 2Researchers discover new producer of crucial vitamin 2
... Researchers at Ume Plant Science Center in Sweden discovered, in ... sugar beets that blocks flowering. Only with the cold of ... to blossom in its second year. The discovery of this ... beets bloom. The new findings were recently published in the ...
... consumed, researchers have learned that up to 90 percent ... the drugs can leave the body almost intact through ... areas, excreted antibiotics can then enter stream and river ... animal feeding operations, fish hatcheries, and nonpoint sources such ...
... Rensselaer Polytechnic Institute assistant professor of chemical and biological ... engineers developing exciting and novel new techniques to treat ... disease, Parkinson,s disease, traumatic brain injury, and brain cancer. ... Goldhirsh Foundation and now has garnered the support of ...
Cached Biology News:New discovery about how flowering time of plants can be controlled 2Virginia Tech engineer identifies new concerns for antibiotic resistance, pollution 2Virginia Tech engineer identifies new concerns for antibiotic resistance, pollution 3Delivering drugs to the brain: New research into targeted treatment of Alzheimer's 2Delivering drugs to the brain: New research into targeted treatment of Alzheimer's 3
Rabbit polyclonal to XPC ( Abpromise for all tested applications). Antigen: Synthetic peptide from N-terminus of Human XPC conjugated to a carrier protein Entrez Gene ID: 7508 Swiss ...
Rabbit polyclonal to FANCG ( Abpromise for all tested applications). Antigen: Synthetic peptide: MSRQTTSVGSSC, corresponding to amino acids 1 - 12 of Human FANCG. Entrez GeneID: 2189 Swis...
Rabbit polyclonal to DcR2 ( Abpromise for all tested applications). entrezGeneID: 8793 SwissProtID: Q9UBN6...
...
Biology Products: